Lexeo Therapeutics (LXEO) Retained Earnings (2022 - 2026)

Lexeo Therapeutics has disclosed Retained Earnings across 5 years of filings, most recently posting -$142000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$142000.0, up 99.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$142000.0 (up 99.95% YoY), and the FY2025 annual result was $188000.0, up 100.07% from the prior year.
• Retained Earnings came in at -$142000.0 for Q1 2026 at Lexeo Therapeutics, down from $188000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $188000.0 in Q4 2025 to a low of -$338.9 million in Q2 2025.
• The 5-year median for Retained Earnings is -$203.3 million (2023), against an average of -$175.0 million.
• Across the five-year window, Retained Earnings sank 57.51% in 2023 and surged 100.07% in 2025, its largest moves.
• Lexeo Therapeutics' Retained Earnings stood at -$115.4 million in 2022, then tumbled by 57.51% to -$181.8 million in 2023, then sank by 54.08% to -$280.2 million in 2024, then jumped by 100.07% to $188000.0 in 2025, then tumbled by 175.53% to -$142000.0 in 2026.
• The last three Retained Earnings figures came in at -$142000.0 (Q1 2026), $188000.0 (Q4 2025), and $89000.0 (Q3 2025), per Business Quant data.